What are the evidence‑based guideline‑recommended treatment options for a patient with pauci‑immune crescentic necrotising glomerulonephritis, serum creatinine 4 mg/dL (non‑dialysis dependent) and 20 % interstitial fibrosis and tubular atrophy, including regimens for both ANCA‑positive and ANCA‑negative disease?

Treatment of Pauci-Immune Crescentic and Necrotising GN with Creatinine 4 mg/dL

For ANCA-positive disease with serum creatinine 4 mg/dL, use glucocorticoids combined with cyclophosphamide as first-line induction therapy, or consider the combination of rituximab plus cyclophosphamide (2 intravenous pulses). For ANCA-negative disease, use the same cyclophosphamide-based regimen with glucocorticoids, as this represents severe disease requiring aggressive immunosuppression despite the absence of detectable antibodies 1.

ANCA-Positive Disease: Induction Therapy Algorithm

Primary Regimen

The 2024 KDIGO guidelines explicitly state that cyclophosphamide is preferred over rituximab monotherapy when serum creatinine exceeds 4 mg/dL (>354 μmol/L) 1. Your patient falls precisely into this category with 20% IFTA indicating some chronicity but still substantial salvageable kidney tissue.

Specific dosing options:

• Oral cyclophosphamide: 2 mg/kg/day for 3 months, continue for ongoing activity to maximum 6 months 1
• Intravenous cyclophosphamide: 15 mg/kg at weeks 0,2,4,7,10,13 (with additional doses at weeks 16,19,21,24 if required) 1

Combined with glucocorticoids using the PEXIVAS reduced-dose regimen:

• Week 1: 50-75 mg prednisolone daily (weight-based: <50 kg = 50 mg; 50-75 kg = 60 mg; >75 kg = 75 mg)
• Taper to 5 mg daily by week 20-22
• Continue 5 mg daily through week 52 1

Alternative: Rituximab Plus Cyclophosphamide Combination

The guidelines specifically note that "a combination of 2 intravenous pulses of cyclophosphamide with rituximab can be considered" in severe GN with creatinine >4 mg/dL 1. This approach:

• Rituximab: 375 mg/m²/week × 4 weeks
• Plus intravenous cyclophosphamide: 15 mg/kg at weeks 0 and 2 only 1

This combination may provide the benefits of both agents while limiting cyclophosphamide exposure.

Glucocorticoid-Sparing Option

Avacopan (C5a receptor blocker) may be used as an alternative to glucocorticoids, particularly beneficial in patients with lower GFR who may achieve greater GFR recovery 1. Dose: 30 mg twice daily 1. This is especially relevant given your patient's creatinine of 4 mg/dL, where preserving remaining kidney function is critical.

ANCA-Negative Disease: Treatment Approach

ANCA-negative pauci-immune crescentic GN should be treated with the same immunosuppressive regimen as ANCA-positive disease 2, 3. The evidence shows:

• Most studies used corticosteroids with cyclophosphamide for induction and azathioprine for maintenance 2
• A French multicenter series of 74 ANCA-negative PICGN patients treated primarily with corticosteroids (98%) and cyclophosphamide (65%) 3
• Despite treatment, ANCA-negative disease has lower renal survival compared to ANCA-positive disease (27% developed kidney failure in one series) 3

Critical distinction: Before initiating immunosuppression in ANCA-negative disease, exclude secondary causes:

• Infection-associated: 12% of ANCA-negative cases 3
• Malignancy-associated: 8% of cases 3, 4
• Drug-induced vasculitis

For primary ANCA-negative disease (77% of cases), use the same cyclophosphamide-based regimen as ANCA-positive disease 3.

Maintenance Therapy (Both ANCA-Positive and ANCA-Negative)

After achieving remission (typically 3-6 months), transition to maintenance therapy:

Preferred option: Rituximab

• 500 mg every 6 months, extending to complete remission until 4 years after diagnosis 1

Alternative options:

• Azathioprine: Start 1.5-2 mg/kg/day for 18-24 months, then decrease to 1 mg/kg/day until 4 years, then taper by 25 mg every 3 months 1
• Mycophenolate mofetil: 2000 mg/day 1

Continue low-dose glucocorticoids: 5-7.5 mg/day for 2 years, then slowly reduce by 1 mg every 2 months 1

Critical Considerations for Your Patient

Favorable Prognostic Factors

• Non-dialysis dependent at creatinine 4 mg/dL indicates preserved urine output
• Only 20% IFTA suggests 80% of kidney tissue may be salvageable with prompt treatment
• These factors support aggressive immunosuppression

Route of Cyclophosphamide Administration

Choose intravenous cyclophosphamide if:

• Patient has ready access to infusion center
• Concern about adherence to daily oral regimen
• Lower white blood cell counts

Choose oral cyclophosphamide if:

• Cost is a major factor
• Limited access to infusion center
• Patient prefers self-administered regimen 1

Plasma Exchange

Not routinely recommended for your patient. The 2024 KDIGO guidelines reserve plasma exchange consideration for:

• Diffuse alveolar bleeding with hypoxemia 1
• Anti-GBM antibody-positive disease
• Refractory disease 1

Your patient with isolated kidney involvement and creatinine 4 mg/dL does not meet these criteria.

Common Pitfalls to Avoid

1. Do not delay treatment waiting for ANCA results - Begin immunosuppression based on biopsy findings of pauci-immune crescentic GN
2. Do not use rituximab monotherapy in this setting - The guidelines explicitly prefer cyclophosphamide when creatinine >4 mg/dL 1
3. Do not undertreate ANCA-negative disease - Use the same aggressive regimen as ANCA-positive disease 2, 3
4. Do not use excessive glucocorticoid doses - The PEXIVAS reduced-dose regimen is adequate and reduces toxicity 1
5. Screen for secondary causes in ANCA-negative disease - Rule out infection and malignancy before attributing to primary vasculitis 3

Monitoring During Treatment

• ANCA persistence or rising titers may predict future relapse and should influence treatment duration decisions 1
• For ANCA-negative disease, relapse rate is approximately 21%, requiring vigilant monitoring 3
• The presence of significant acute tubulointerstitial injury (beyond glomerular injury) contributes substantially to AKI in ANCA GN and may influence recovery potential 5